Incyte Co. (NASDAQ:INCY) insider David W. Gryska sold 6,760 shares of Incyte stock in a transaction on Friday, January 5th. The shares were sold at an average price of $98.87, for a total value of $668,361.20. Following the completion of the transaction, the insider now owns 20,752 shares in the company, valued at approximately $2,051,750.24. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Incyte Co. (NASDAQ:INCY) opened at $96.62 on Thursday. The company has a market capitalization of $20,390.00, a PE ratio of -120.78 and a beta of 0.74. Incyte Co. has a twelve month low of $92.91 and a twelve month high of $153.15. The company has a current ratio of 4.82, a quick ratio of 4.81 and a debt-to-equity ratio of 0.01.
Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.11. The firm had revenue of $381.50 million for the quarter, compared to the consensus estimate of $360.34 million. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. The business’s quarterly revenue was up 41.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.19 EPS. equities analysts anticipate that Incyte Co. will post -1.32 earnings per share for the current fiscal year.
INCY has been the topic of several recent analyst reports. Argus reiterated a “buy” rating and issued a $150.00 price target on shares of Incyte in a research note on Wednesday, September 13th. Royal Bank of Canada initiated coverage on Incyte in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $136.00 price target on the stock. Jefferies Group reiterated a “buy” rating on shares of Incyte in a research note on Friday, October 6th. Goldman Sachs Group initiated coverage on Incyte in a research note on Friday, October 6th. They issued a “buy” rating and a $160.00 price target on the stock. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Incyte in a research note on Wednesday, October 25th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Incyte has a consensus rating of “Buy” and an average price target of $143.11.
A number of institutional investors and hedge funds have recently made changes to their positions in INCY. Los Angeles Capital Management & Equity Research Inc. acquired a new position in Incyte during the 2nd quarter worth about $2,538,000. Oak Ridge Investments LLC lifted its stake in shares of Incyte by 9.1% in the 2nd quarter. Oak Ridge Investments LLC now owns 92,978 shares of the biopharmaceutical company’s stock valued at $11,707,000 after purchasing an additional 7,767 shares during the period. Riverhead Capital Management LLC lifted its stake in shares of Incyte by 22.0% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,030 shares of the biopharmaceutical company’s stock valued at $381,000 after purchasing an additional 546 shares during the period. Symphony Asset Management LLC lifted its stake in shares of Incyte by 20.1% in the 2nd quarter. Symphony Asset Management LLC now owns 1,867 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 312 shares during the period. Finally, Seven Eight Capital LP acquired a new position in shares of Incyte in the 2nd quarter valued at about $129,000. 90.74% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/11/david-w-gryska-sells-6760-shares-of-incyte-co-incy-stock.html.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.